Detailed dose evidence documented for Bivalirudin in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
PCI: 0.75 mg/kg IV bolus, immediately followed by 1.75 mg/kg/h IV infusion for the procedure duration and up to 4 h post-procedure. Continue at 0.2 mg/kg/h for up to 20 h if needed. Reduce infusion to 1.0 mg/kg/h in severe renal impairment (CrCl less than 30 mL/min). Use with aspirin 300-325 mg daily.
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
BAT regimen (1 mg/kg bolus + 2.5/0.2 mg/kg/h infusion) is not the current PCI-recommended dose.
Not established
What is not established
ACS patients not undergoing PCI (limitation of use per label).
Coronary artery bypass grafting (studied but not labeled; associated with higher rates of bypass-graft occlusion in some studies).